Dexrazoxane: A Review of its Use for Cardioprotection During Anthracycline Chemotherapy

ISSN： 0012-6667

Source： Drugs, Vol.65, Iss.7, 2005-01, pp. : 1005-1024

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Dexrazoxane: A Review of its Use as a Cardioprotective Agent in Patients Receiving Anthracycline-Based Chemotherapy

By Wiseman L.R. Spencer C.M.

Drugs, Vol. 56, Iss. 3, 1998-09 ,pp. : 385-403

Adis International

Access to resources Recommend Favorite

The use of dexrazoxane for the prevention of anthracycline extravasation injury

By Hasinoff Brian B

Expert Opinion on Investigational Drugs, Vol. 17, Iss. 2, 2008-02 ,pp. : 217-223

Informa Healthcare

Access to resources Recommend Favorite

Aprepitant: A Review of its Use in the Prevention of Chemotherapy-Induced Nausea and Vomiting

By Dando T.M. Perry C.M.

Drugs, Vol. 64, Iss. 7, 2004-01 ,pp. : 777-794

Adis International

Access to resources Recommend Favorite

The cardioprotective effect of the iron chelator dexrazoxane (ICRF-187) on anthracycline-mediated cardiotoxicity

By Kwok J.C. Richardson D.R.

Redox Report, Vol. 5, Iss. 6, 2000-12 ,pp. : 317-324

Maney Publishing

Access to resources Recommend Favorite

Dexrazoxane for the Prevention of Cardiac Toxicity and Treatment of Extravasation Injury from the Anthracycline Antibiotics

Current Pharmaceutical Biotechnology, Vol. 13, Iss. 10, 2012-08 ,pp. : 1949-1956

Bentham Science Publishers

Access to resources Recommend Favorite